These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17021015)

  • 21. Electron paramagnetic resonance reveals altered topography of the active center gorge of acetylcholinesterase after binding of fasciculin to the peripheral site.
    Sentjurc M; Pecar S; Stojan J; Marchot P; Radić Z; Grubic Z
    Biochim Biophys Acta; 1999 Mar; 1430(2):349-58. PubMed ID: 10082962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex.
    Bourne Y; Taylor P; Marchot P
    Cell; 1995 Nov; 83(3):503-12. PubMed ID: 8521480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic peptides mimicking the binding site of human acetylcholinesterase for its inhibitor fasciculin 2.
    Kafurke U; Erijman A; Aizner Y; Shifman JM; Eichler J
    J Pept Sci; 2015 Sep; 21(9):723-30. PubMed ID: 26200472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The binding sites of inhibitory monoclonal antibodies on acetylcholinesterase. Identification of a novel regulatory site at the putative "back door".
    Simon S; Le Goff A; Frobert Y; Grassi J; Massoulié J
    J Biol Chem; 1999 Sep; 274(39):27740-6. PubMed ID: 10488117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organophosphorylation of acetylcholinesterase in the presence of peripheral site ligands. Distinct effects of propidium and fasciculin.
    Mallender WD; Szegletes T; Rosenberry TL
    J Biol Chem; 1999 Mar; 274(13):8491-9. PubMed ID: 10085081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site of fasciculin interaction with acetylcholinesterase.
    Radić Z; Duran R; Vellom DC; Li Y; Cervenansky C; Taylor P
    J Biol Chem; 1994 Apr; 269(15):11233-9. PubMed ID: 8157652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 125I-labeled fasciculin 2: a new tool for quantitation of acetylcholinesterase densities at synaptic sites by EM-autoradiography.
    Anglister L; Eichler J; Szabo M; Haesaert B; Salpeter MM
    J Neurosci Methods; 1998 Jun; 81(1-2):63-71. PubMed ID: 9696311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The entropic cost of protein-protein association: a case study on acetylcholinesterase binding to fasciculin-2.
    Minh DD; Bui JM; Chang CE; Jain T; Swanson JM; McCammon JA
    Biophys J; 2005 Oct; 89(4):L25-7. PubMed ID: 16100267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse acetylcholinesterase unliganded and in complex with huperzine A: a comparison of molecular dynamics simulations.
    Tara S; Straatsma TP; McCammon JA
    Biopolymers; 1999 Jul; 50(1):35-43. PubMed ID: 10341665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allosteric control of acetylcholinesterase activity by monoclonal antibodies.
    Saxena A; Hur R; Doctor BP
    Biochemistry; 1998 Jan; 37(1):145-54. PubMed ID: 9425034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Binding conformation prediction between human acetylcholinesterase and cytochrome c using molecular modeling methods.
    Kim S; Lee Y; Lazar P; Son M; Baek A; Thangapandian S; Jeong NY; Yoo YH; Lee KW
    J Mol Graph Model; 2011 Aug; 29(8):996-1005. PubMed ID: 21570330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In silico analysis of binding of neurotoxic venom ligands with acetylcholinesterase for therapeutic use in treatment of Alzheimer's disease.
    Waqar M; Batool S
    J Theor Biol; 2015 May; 372():107-17. PubMed ID: 25747777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conformers of acetylcholinesterase: a mechanism of allosteric control.
    Taylor JL; Mayer RT; Himel CM
    Mol Pharmacol; 1994 Jan; 45(1):74-83. PubMed ID: 8302283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein-protein association: investigation of factors influencing association rates by brownian dynamics simulations.
    Gabdoulline RR; Wade RC
    J Mol Biol; 2001 Mar; 306(5):1139-55. PubMed ID: 11237623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural evidence that human acetylcholinesterase inhibited by tabun ages through O-dealkylation.
    Carletti E; Colletier JP; Dupeux F; Trovaslet M; Masson P; Nachon F
    J Med Chem; 2010 May; 53(10):4002-8. PubMed ID: 20408548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrinsic conformational flexibility of acetylcholinesterase.
    Bui JM; Andrew McCammon J
    Chem Biol Interact; 2008 Sep; 175(1-3):303-4. PubMed ID: 18452905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and characterization of a chimeric peptide derived from fasciculin that inhibits acetylcholinesterase.
    Falkenstein RJ; Gornalusse GG; Peña C
    J Pept Sci; 2004 Jun; 10(6):342-9. PubMed ID: 15214439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of the acetylcholinesterase active site protonation on omega loop and active site dynamics.
    Wiesner J; Kříž Z; Kuča K; Jun D; Koča J
    J Biomol Struct Dyn; 2010 Dec; 28(3):393-403. PubMed ID: 20919754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting the rate enhancement of protein complex formation from the electrostatic energy of interaction.
    Selzer T; Schreiber G
    J Mol Biol; 1999 Mar; 287(2):409-19. PubMed ID: 10080902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability of a structural scaffold upon activity transfer: X-ray structure of a three fingers chimeric protein.
    Le Du MH; Ricciardi A; Khayati M; Ménez R; Boulain JC; Ménez A; Ducancel F
    J Mol Biol; 2000 Mar; 296(4):1017-26. PubMed ID: 10686100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.